Sexual Health & Libido
Research compounds studied for central arousal pathways, hormonal axis restoration, and sexual response enhancement. Includes FDA-approved compounds and hormonal modulators.
Most researched for Sexual Health & Libido
PT-141
The only compound in this category with FDA approval for a sexual health indication (female hypoactive sexual desire disorder under the name Vyleesi). PT-141 activates melanocortin receptors in the brain to increase sexual desire centrally - a distinct mechanism from PDE5 inhibitors (Viagra/Cialis) which work peripherally. On-demand dosing, fast onset, validated across genders in clinical research.
Nafarelin
aka Synarel
How it works: A nasal hormone peptide that briefly spikes then suppresses sex hormones, used medically for hormone-driven conditions.
Endometriosis (FDA); central precocious puberty (FDA); menstrual cycle control
Research dose
200-400 mcg, Twice daily intranasal (Synarel label)
Real-world (reported)
Primarily Rx-driven.
Administration
Intranasal
Timing
Twice daily (AM + PM)
Cycle length
6 months max per FDA label
Real-world figures are community-reported, not medical advice.
Common side effects: Hot flashes; vaginal dryness; decreased libido; nasal irritation; bone loss long use
Community take: [ANECDOTAL] Primarily Rx medical. Limited gray-market interest in menstrual cycle and IVF protocols.
- Onset
- Hormonal suppression 2–4 wks
- Half-life
- ~2–5h
- Storage
- Dry: Refrigerate 2–8°C; do not freeze · Reconstituted: Refrigerate; follow label
- Reconstitution
- N/A (pre-formulated nasal spray)
- Rare side effects
- Bone density loss (>6 mo — limit treatment); depression; menopausal symptoms; testosterone suppression (males)
- Contraindications
- Pregnancy; hormone-sensitive cancers (flare before suppression); osteoporosis
- Drug interactions
- Estrogen/testosterone (antagonistic); bone loss meds
- Recommended bloodwork
- Bone density (DEXA if >6 mo); LH; FSH; estradiol/testosterone; CBC
- Stacks well with
- Add-back therapy required for >6 mo endometriosis (FDA label — estrogen/progesterone).
- Secondary uses
- IVF down-regulation; hormone-sensitive cancer (research)
- Research status
- FDA-approved Synarel; Phase 3 endometriosis and CPP
- FDA status
- No
- Legal status
- US: FDA-approved (Synarel) · UK: Prescription-only · Canada: Prescription-only · Australia: TGA-approved (Rx) · EU: EMA-approved (Rx)
- Typical price
- Brand ~$200–$400/month
Melanotan II
aka MT-2, MT-II, MT2
How it works: Activates melanocortin receptors to stimulate melanin production, providing UV-induced pigmentation and some photoprotection.
Skin tanning/pigmentation; libido enhancement; erectile function
Research dose
250-1000 mcg, Daily (loading) then maintenance 2–3×/week
Real-world (reported)
Start low 250 mcg; build to 500–1000 mcg. Evening dose to sleep through nausea. UV exposure needed for tanning effect.
Administration
SubQ
Timing
Evening (nausea management)
Cycle length
Loading 1–2 wks; maintenance ongoing (with UV exposure for tanning)
Real-world figures are community-reported, not medical advice.
Common side effects: Nausea (common, especially first dose); flushing; facial flushing; spontaneous erections (males); darkening of existing moles
Community take: [ANECDOTAL] Very popular for tanning. 'Barbie drug' in media. Community concern about mole changes — dermatology visits recommended. Libido effect strong.
- Onset
- Tanning 2–4 wks with UV; libido hours
- Half-life
- ~33h (Cmax ~1h)
- Storage
- Dry: Fridge 2–8°C; freeze long-term; protect from light · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 2 mL BAC water to 10 mg vial = 5 mg/mL; 500 mcg dose = 10 IU
- Rare side effects
- Darkening/enlargement of moles (melanoma risk concern); melanoma case reports; prolonged erection; hypertension; hyperpigmentation of normal skin
- Contraindications
- Personal or family history of melanoma; active malignancy; pregnancy; cardiovascular disease; PT-141 preferred for pure sexual health (fewer pigmentation concerns); Uncontrolled hypertension or significant cardiovascular disease; History or risk of priapism; Pregnancy and lactation; Severe renal impairment
- Drug interactions
- Antihypertensives (additive BP effects); sexual function medications
- Recommended bloodwork
- Dermatology check (mole mapping) before and every 6 months; BP monitoring
- Stacks well with
- PT-141 (more selective; no tanning — choose one or the other based on goal).
- Secondary uses
- Appetite suppression; fat loss (secondary)
- Research status
- Mostly preclinical and Phase 1/2 human data; not FDA-approved; under FDA PCAC review
- FDA status
- No
- Legal status
- US: Research use only; PCAC review pending; Import Alert 66-78 · UK: Legal for research; not scheduled · Canada: Legal research chemical · Australia: Schedule 4; importation risk · EU: Unregulated most EU
- Typical price
- $25–$60 / 10 mg vial
- Research evidence
- low
- Indications
- Melanogenesis and tanning research; Melanocortin receptor pharmacology studies; Sexual function research (led to development of PT-141); Appetite regulation and energy homeostasis studies
- Chemical data
- CAS 121062-08-6 · C50H69N15O9 · 1024.18 Da
- Amino acids
- 243 aa
Kisspeptin-10
aka KP-10, Metastin (45-54), Kisspeptin-54
How it works: Stimulates hypothalamic GnRH pulses to restore the hormonal axis and increase baseline testosterone and estrogen levels.
LH pulse stimulation; testosterone elevation; reproductive axis activation; fertility support
Research dose
0.3-3 mcg/kg, Pulsatile: every 90 min (physiological); practical: 1–2 ×/day SubQ
Real-world (reported)
50–100 mcg SubQ 1–2×/day. Very limited community protocols — follow clinical trial dosing.
Administration
SubQ / IV (clinical)
Timing
Morning and/or pre-sleep
Cycle length
Cyclical use; 2–4 wks on; break
Real-world figures are community-reported, not medical advice.
Common side effects: Injection-site reactions; mild flushing; transient LH surge
Community take: [ANECDOTAL] Very new in community. Used by biohackers for HPG axis optimization. 'Upstream of everything.' Limited gray-market experience.
- Onset
- LH pulse within hours; testosterone elevation 1–2 wks
- Half-life
- ~30 min
- Storage
- Dry: Fridge 2–8°C; freeze long-term; very light sensitive · Reconstituted: Refrigerate; use within 14–21 days
- Reconstitution
- Add 1 mL BAC water to 1 mg vial = 1 mg/mL
- Rare side effects
- Desensitization with continuous non-pulsatile use (like GnRH analogs)
- Contraindications
- Hormone-sensitive cancers; pregnancy (causes GnRH overstimulation); continuous infusion (desensitizes); Sex hormone-sensitive cancers (breast; endometrial; ovarian; prostate) due to ki; Pregnancy (kisspeptin stimulates gonadotropin release which could disrupt early; Central precocious puberty (exogenous kisspeptin could further stimulate prematu; GnRH agonists and antagonists (pharm
- Drug interactions
- GnRH analogs; sex hormones; GPR54 modulators
- Recommended bloodwork
- LH (pre/post injection); testosterone; FSH; estradiol; LH pulsatility assessment
- Stacks well with
- Gonadorelin: complementary (different upstream levels of HPG axis). Both for TRT axis maintenance.
- Secondary uses
- Libido; mood; metabolic regulation; potential anti-tumor (emerging)
- Research status
- Human Phase 1/2 clinical trials for reproductive disorders and hypogonadism; solid human pharmacokinetic data
- FDA status
- No
- Legal status
- US: Research use only; not scheduled · UK: Legal for research · Canada: Legal research chemical · Australia: Schedule 4 · EU: Unregulated
- Typical price
- $50–$120 / 1 mg vial
- Research evidence
- moderate
- Indications
- Fertility and IVF research; Puberty onset studies; Reproductive endocrinology; Hypothalamic amenorrhea investigation
- Chemical data
- CAS 374675-21-5 · C257H383N69O74S3 · 5861.5 Da
- Amino acids
- 258 aa
Gonadorelin
aka GnRH, LH-RH, Factrel
How it works: Identical to the body's own GnRH signal; pulsed dosing prompts LH and FSH, used to maintain testicular function during TRT and support fertility.
LH and FSH stimulation; testicular function maintenance during TRT; post-cycle fertility support
Research dose
100-500 mcg, Pulsatile: every 90–120 min (physiological); practical: 2×/day SubQ
Real-world (reported)
100–200 mcg SubQ 2×/day (morning + evening) during TRT. Some use 500 mcg 2×/day. Switch to pulsatile dosing device if available.
Administration
SubQ / IM / Intranasal
Timing
Morning + evening (practical pulsatile approximation)
Cycle length
Ongoing (TRT adjunct); or 4–8 wks (fertility/PCT)
Real-world figures are community-reported, not medical advice.
Common side effects: Injection-site reactions; mild flushing; headache (rare)
Community take: [ANECDOTAL – TRT community] Standard TRT adjunct to maintain testicular size and function. 'Keeps the boys working.' Preferred over HCG by some due to more physiological mechanism.
- Onset
- LH/FSH rise within hours; testicular volume 4–12 wks
- Half-life
- ~2–10 min
- Storage
- Dry: Fridge 2–8°C; freeze long-term · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 2 mL BAC water to 2 mg vial = 1 mg/mL; 100 mcg = 10 IU
- Rare side effects
- Overstimulation syndrome (rare in males); anaphylaxis (rare); desensitization with continuous use
- Contraindications
- Pregnancy (if female partner using); hormone-sensitive cancers; continuous (non-pulsatile) use causes suppression; Pregnancy (potential effects on embryo/placental processes); Known hypersensitivity to gonadorelin or GnRH analogs; Hormone-sensitive reproductive tumors (theoretical concern); Lactation (GnRH-like bioactive peptides present in milk)Frequency distribution o
- Drug interactions
- GnRH analogs; sex hormones; prostate cancer medications
- Recommended bloodwork
- LH; FSH; testosterone; testicular volume; sperm count if fertility is goal
- Stacks well with
- HCG: alternative for LH/FSH stimulation on TRT. Kisspeptin-10: upstream stimulation.
- Secondary uses
- Prevent testicular atrophy on TRT; fertility preservation; hypogonadism treatment
- Research status
- FDA-approved for diagnostic use (Factrel); widely used off-label in TRT protocols; solid human data
- FDA status
- No
- Legal status
- US: FDA-approved diagnostic use; off-label Rx compounding; research chemical gray-market · UK: Legal for research; Rx compounding available · Canada: Legal; Rx compounding · Australia: Schedule 4 (Rx) · EU: Varies by EU state
- Typical price
- $30–$70 / 2 mg vial
- Research evidence
- moderate
- Indications
- Diagnostic testing of hypothalamic-pituitary-gonadal axis; Fertility treatment support; Hormone replacement therapy adjunct; Research into reproductive endocrinology
- Chemical data
- CAS 33515-09-2 · C55H75N17O13 · 1182.29 Da
- Amino acids
- 244 aa
Triptorelin
aka Decapeptyl, Trelstar, D-Trp6-LHRH
How it works: A hormone peptide that, in a single low dose, can restart the body's natural testosterone signaling - while continuous use instead suppresses it.
Post-cycle therapy (PCT) hormonal restart; testosterone recovery after anabolic steroid use
Research dose
100-500 mcg, PCT: SINGLE DOSE only (one injection); medical: depot injection q1–3 months
Real-world (reported)
100 mcg SubQ single dose. Wait 2–3 days then begin SERM if needed. Very advanced use — proceed only with bloodwork.
Administration
SubQ / IM / SC depot
Timing
PCT: single injection timing varies by protocol
Cycle length
PCT: single dose, then wait for HPG restart; medical: chronic
Real-world figures are community-reported, not medical advice.
Common side effects: Hot flashes; injection-site reactions; testosterone flare then crash (with continuous dosing)
Community take: [ANECDOTAL – bodybuilding community] 'Nuclear option' for PCT restart. Single 100 mcg dose used by some after heavy AAS cycles. Works when SERMs fail. Community experience limited vs conventional PCT.
- Onset
- LH surge within 4–8h of PCT dose; testosterone rise 1–2 wks
- Half-life
- ~7–8h half-life (non-depot)
- Storage
- Dry: Fridge 2–8°C; protect from light · Reconstituted: Refrigerate; use within 28 days
- Reconstitution
- Add 1 mL BAC water to 0.1 mg vial = 0.1 mg/mL
- Rare side effects
- Testosterone crash with repeated dosing (suppression); reduced bone density long-term (medical use); anaphylaxis (rare)
- Contraindications
- Prostate cancer (stimulates before suppressing — tumor flare); pregnancy; ongoing steroid use; Known hypersensitivity to triptorelin; GnRH; or any GnRH agonist; Pregnancy (Category X - may cause fetal harm); Breastfeeding; Undiagnosed abnormal vaginal bleedingFrequency distribution of reported side eff
- Drug interactions
- Sex hormones; antiandrogens; drugs affecting QT interval
- Recommended bloodwork
- LH; FSH; testosterone; estradiol; SHBG — timing-specific post-PCT
- Stacks well with
- SERMs (Clomid, Nolvadex): sometimes used after triptorelin PCT to maintain restart.
- Secondary uses
- Prostate cancer treatment (FDA-approved); endometriosis; gender-affirming care
- Research status
- FDA-approved for prostate cancer and endometriosis (continuous dosing); off-label PCT use (single pulsatile dose)
- FDA status
- No
- Legal status
- US: FDA-approved (medical uses); off-label PCT use as research chemical · UK: Prescription-only (medical); research chemical off-label · Canada: Legal research chemical · Australia: Schedule 4 (Rx) · EU: Prescription-regulated
- Typical price
- $30–$80 / 0.1 mg vial
- Research evidence
- high
- Indications
- Advanced prostate cancer treatment (androgen deprivation therapy); Endometriosis management; Central precocious puberty treatment; Uterine fibroid symptom management
- Chemical data
- CAS 57773-63-4 · C64H82N18O13 · (Da
- Amino acids
- 246 aa
Oxytocin
aka Pitocin, OT, Syntocinon
How it works: Activates oxytocin receptors in the brain to enhance social bonding, emotional connection, and intensity of sexual response.
Social bonding; trust; intimacy; sexual arousal; orgasm intensity enhancement
Research dose
20-40 IU, As needed; intranasal or SubQ
Real-world (reported)
20–40 IU intranasal spray 20–30 min before social/sexual activity. Start at 20 IU.
Administration
Intranasal (most practical); SubQ (research); IV (medical obstetrics only)
Timing
20–45 min before desired effect
Cycle length
As needed (not cycled)
Real-world figures are community-reported, not medical advice.
Common side effects: Headache; nausea; flushing; uterine contractions (females — significant risk if pregnant)
Community take: [ANECDOTAL] Popular for intimacy/social contexts. 'Love hormone' effect widely reported. Some use PT-141 + oxytocin combo. Variable response — highly individual.
- Onset
- Social/emotional effects within 30–45 min; sexual effects within 20–30 min
- Half-life
- ~1–2h (intranasal)
- Storage
- Dry: Nasal spray: refrigerate; follow mfr guidelines · Reconstituted: SubQ reconstituted: refrigerate; use within 21 days
- Reconstitution
- Nasal spray: pre-filled or custom pharmacy. SubQ: add BAC water.
- Rare side effects
- Uterine hyperstimulation (DANGEROUS in pregnancy — can cause fetal distress/death); water intoxication (rare at high doses); excessive trust/social manipulation vulnerability
- Contraindications
- PREGNANCY (can induce labor/fetal distress — CONTRAINDICATED); cardiovascular disease; history of hyponatremia; Significant cephalopelvic disproportion; Unfavorable fetal positions (transverse lie); Cord presentation or prolapse; Placenta previa or vasa previa
- Drug interactions
- Antihypertensives; SSRIs (complex serotonin/oxytocin interaction); vasoconstrictors
- Recommended bloodwork
- Sodium levels (hyponatremia risk at high doses); BP
- Stacks well with
- PT-141: reported additive sexual effects [ANECDOTAL]. Avoid combining with other vasodilators.
- Secondary uses
- Anti-anxiety; empathy; prosocial behavior; post-workout recovery; lactation (endogenous role)
- Research status
- FDA-approved (Pitocin — obstetrics only); off-label intranasal use extensively studied in social/psychiatric contexts; solid human pharmacology data
- FDA status
- No
- Legal status
- US: FDA-approved (obstetrics only); off-label intranasal research use · UK: Legal; Rx for obstetrics; research use off-label · Canada: Legal; Rx compounding · Australia: Schedule 4 (Rx) · EU: Prescription-regulated most EU
- Typical price
- $20–$50 / research nasal spray
- Research evidence
- high
- Indications
- Labor induction and augmentation; Postpartum hemorrhage prevention and treatment; Social cognition and autism spectrum disorder research; Anxiety and stress-related disorder studies; PTSD treatment augmentation research; Pair bonding and trust research
- Chemical data
- CAS 50-56-6 · C43H66N12O12S2 · 1007.19 Da
- Amino acids
- 83 aa
Alprostadil
aka Prostaglandin E1, PGE1, Caverject
How it works: Alprostadil is a synthetic form of prostaglandin E1 (PGE1), an endogenous lipid mediator with potent vasodilatory and anti-platelet properties. While not a peptide, it is FDA-approved for the treatment of erectile dysfunction (intracavernosal injection and intraurethral suppository) and for maintaining patent ductus arteriosus in neonates. It is also used off-label for critical limb ischemia and p
Erectile dysfunction treatment; Critical limb ischemia management; Patent ductus arteriosus maintenance in neonates; Peripheral arterial disease
Administration
IM
Timing
As needed before sexual activity (ED); continuous infusion (PDA)
Cycle length
Ongoing as needed for ED; until surgical correction for PDAStep-wise Titration
- Half-life
- Approximately
- Storage
- Dry: Caverject lyophilized powder: store at or below 25 degrees C (77 degrees F). Reconstituted solution: use within 24 hours; do not refrigerate or freeze
- Reconstitution
- D5W or normal saline
- Contraindications
- Conditions predisposing to priapism: sickle cell disease or trait, multiple myel; Penile anatomical deformities: severe hypospadias, cavernosal fibrosis, Peyronie; Penile implants (for intracavernosal and intraurethral use); Urethral stricture, balanitis, or acute urethritis (for MUSE intraurethral use)
- Research status
- Approved
- FDA status
- FDA approved
- Legal status
- US: Approved
- Research evidence
- high
- Indications
- Erectile dysfunction treatment; Critical limb ischemia management; Patent ductus arteriosus maintenance in neonates; Peripheral arterial disease
- Chemical data
- CAS 745-65-3 · C20H34O5 · 354.48 Da
- Amino acids
- 51 aa
HCG
aka Human Chorionic Gonadotropin, Pregnyl, Novarel
How it works: HCG (Human Chorionic Gonadotropin) is a glycoprotein hormone composed of alpha and beta subunits. It mimics luteinizing hormone (LH) activity and is FDA-approved for treatment of hypogonadism, cryptorchidism, and as part of assisted reproductive technology protocols.New to reproductive peptides?Browse all reproductive peptides →Table of Contents📌TL;DR•FDA-approved for multiple reproductive indica
Male hypogonadism treatment; Ovulation induction in fertility treatments; Cryptorchidism treatment in pediatric patients; Testosterone restoration adjunct therapy
Administration
SC
Timing
No specific time of day; maintain consistent schedule✓ Rotate injection sites
Cycle length
Ongoing while on TRT; or 6-12 weeks for PCT/fertility protocols
- Half-life
- and charge without directly mediating receptor binding.
- Reconstitution
- Bacteriostatic water
- Contraindications
- Pregnancy (risk of virilization/teratogenicity); Androgen-dependent or estrogen-dependent tumors (prostate cancer, breast cancer); Undiagnosed ovarian enlargement or ovarian cysts; Precocious puberty
- Research status
- Approved
- FDA status
- FDA approved
- Legal status
- US: Approved
- Research evidence
- low
- Indications
- Male hypogonadism treatment; Ovulation induction in fertility treatments; Cryptorchidism treatment in pediatric patients; Testosterone restoration adjunct therapy
- Chemical data
- CAS 9002-61-3 · Glycoprotein heterodimer (~25.7 kDa peptide + ~10-15 kDa glycans) · 36700 Da
- Amino acids
- 156 aa
HMG
aka Human Menopausal Gonadotropin, Menotropin, Menopur
How it works: HMG (Human Menopausal Gonadotropin) is a purified preparation of gonadotropins extracted from the urine of postmenopausal women, containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity. It is FDA-approved for ovulation induction and controlled ovarian hyperstimulation in assisted reproduction.New to reproductive peptides?Browse all reproductive peptides →Table of C
Controlled ovarian hyperstimulation for IVF; Ovulation induction in anovulatory women; Male hypogonadotropic hypogonadism treatment; Fertility research and reproductive endocrinology
Administration
SC
Timing
No specific time of day; consistency is key✓ Rotate injection sites
Cycle length
7-20 days per cycle (women, monitored); 3-6 months (men, spermatogenesis)
- Half-life
- and time course
- Contraindications
- Primary ovarian failure; Uncontrolled thyroid or adrenal insufficiency; Sex hormone-dependent tumors; Unexplained uterine bleeding
- Research status
- Approved
- FDA status
- FDA approved
- Legal status
- US: Approved
- Research evidence
- low
- Indications
- Controlled ovarian hyperstimulation for IVF; Ovulation induction in anovulatory women; Male hypogonadotropic hypogonadism treatment; Fertility research and reproductive endocrinology
- Chemical data
- CAS 9002-68-0 · Glycoprotein mixture (FSH ~35.5 kDa + LH ~28.5 kDa) · 35000 Da
- Amino acids
- 106 aa
LIB-01
aka Libiguin, LIB-01 Monohydrate
How it works: LIB-01 is a first-in-class oral compound developed by Dicot Pharma for the treatment of erectile dysfunction. Derived from phragmalin limonoids (libiguins) isolated from the Madagascan plant Neobeguea mahafalensis, LIB-01 modulates melanocortin-4 receptor (MC4R) signaling in the central nervous system to enhance erectile function. Its most distinctive feature is a remarkably long duration of actio
Erectile dysfunction treatment; Potential applications in premature ejaculation; Investigational use in metabolic diseases (preclinical)
Administration
Oral
Timing
Oral tablet taken once daily for 3 consecutive days. Unique pharmacodynamic profile with onset within 7 days and sustained effect for 4-8 weeks after
Cycle length
3-day course; effects last 4-8 weeks
- Half-life
- Short plasma half-life (exact value not publicly disclosed); pharmacodynamic eff
- Contraindications
- Not established -- LIB-01 is an investigational compound and formal contraindica; Women of childbearing potential should not use LIB-01 outside of clinical trials; No drug-drug interaction data have been published for LIB-01. Potential interact
- Research status
- Phase 2a
- Legal status
- US: Investigational
- Research evidence
- moderate
- Indications
- Erectile dysfunction treatment; Potential applications in premature ejaculation; Investigational use in metabolic diseases (preclinical)
- Chemical data
- C37H48O13 · 698.77 Da
- Amino acids
- 79 aa
MVT-602
aka TAK-448, RVT-602
How it works: MVT-602 (TAK-448) is a synthetic kisspeptin receptor (KISS1R) agonist developed by Myovant Sciences for use as an oocyte maturation trigger during in vitro fertilization (IVF). This nonapeptide analog of kisspeptin produces a prolonged, physiological LH surge lasting 21-22 hours (versus 4.7 hours for native kisspeptin-54), with a 4-fold greater LH area under the curve. By triggering ovulation thro
Oocyte maturation trigger during IVF/medically assisted reproduction; Potential treatment for anovulatory disorders; Investigational use in hypogonadotropic hypogonadism
Administration
SC
Timing
Administered as a single injection to trigger oocyte maturation; LH surge peaks at 21-22 hours post-dose
Cycle length
Single administration
- Half-life
- enhancement, and pharmacokinetic properties.","url":"https://www.peptideprotocol
- Contraindications
- Not established -- MVT-602 is investigational and formal contraindications have; Pregnancy (kisspeptin signaling modulates reproductive axis; effects on early pr; Known KISS1R-related conditions where additional kisspeptin signaling stimulatio; GnRH agonists and antagonists may interfere with MVT-602 mechanism since MVT-602
- Research status
- Phase 2a
- Legal status
- US: Investigational
- Research evidence
- moderate
- Indications
- Oocyte maturation trigger during IVF/medically assisted reproduction; Potential treatment for anovulatory disorders; Investigational use in hypogonadotropic hypogonadism
- Chemical data
- CAS 1234319-68-6 · C58H80N16O14 · 1225.36 Da
- Amino acids
- 251 aa
Example stacks
Libido - Beginner
PT-141 on-demand is the simplest and most validated starting point. FDA-approved for female sexual dysfunction.
- • Start at 0.5 mg and assess before moving to 1 mg
- • Allow the full 1-2 hr onset window
- • Inject in the abdomen or thigh
Libido - Intermediate
Kisspeptin-10 restores baseline hormonal signaling. PT-141 handles on-demand arousal. Addresses both the root hormonal cause and immediate response.
- • Space Kisspeptin evenly - e.g. Mon, Wed, Fri
- • Give Kisspeptin 4+ weeks to show hormonal effects
- • Test testosterone and estrogen before and after the cycle
Community outcome data
Collected from users researching this goal. Not a clinical database - for general reference only.
Share your experience
Your experience helps others research this goal. All submissions are anonymous.
Ready to actually use this research?
FREETwo tools that turn this research into something you can actually use - no signup needed.
For educational and research purposes only. Not medical advice. Always consult a qualified healthcare provider before using any research compound.